A new model for estimation of significant fibrosis in primary care. SAFE to use?

肝活检 人口 肝病 估计 医学 重症监护医学 危害 疾病 阶段(地层学) 医疗保健 采样(信号处理) 活检 内科学 环境卫生 计算机科学 古生物学 法学 管理 经济 政治学 滤波器(信号处理) 生物 经济增长 计算机视觉
作者
Hannes Hagström
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:77 (1): 18-19
标识
DOI:10.1002/hep.32549
摘要

While non‐alcoholic fatty liver disease (NAFLD) is the most common liver disease globally, few patients develop clinically significant liver‐related events.1 Correct estimation of patients at risk for such outcomes is of high importance. It is now well established that fibrosis stage is the key determinant of liver‐related outcomes in NAFLD, and also predicts overall mortality.2,3 However, much research focus is made to step away from use of liver biopsy as a diagnostic and prognostic tool since biopsies are expensive, has the potential for harm, and results can be difficult to interpret due to sampling error and poor intra‐ and inter‐reader reproducibility, especially regarding the presence of ballooning.4 Therefore, developing non‐invasive alternatives to biopsy is a subject of high interest to patients and clinicians, as well as healthcare payers. Since most patients with NAFLD are found in primary care, a first step is to estimate the probability for presence (or absence) of clinically significant hepatic fibrosis. This is usually agreed as being stage 2–4 on the NASH CRN scale.5 Given the magnitude of the population at risk (possibly up to 25%), tools to use in a primary care setting needs to be simple, inexpensive and easy to interpret for primary care physicians. Developing such tools have been shown to be difficult. The commonly used FIB‐4 score for instance,6 was found to lack specificity and sensitivity when used in a primary care population.7 Efforts to improve first‐line diagnostics in this field are therefore highly warranted, especially since both FIB‐4 and other scores are mostly developed to identify stage 3–4 fibrosis, while inclusion in clinical trials normally requires presence of stage 2–3 fibrosis and patients with stage 2 fibrosis also have an increased risk for outcomes compared to those with minimal fibrosis.2 In this issue of Hepatology, Sripongpun and colleagues present a new diagnostic model for detection of stage 2–4 fibrosis in patients with NAFLD. The intention was to improve primary care decision‐making on when to retain the patient in primary care, and when to refer to other services in the healthcare system. The Steatosis‐Associated Fibrosis Estimator (SAFE) score was constructed using data from 676 patients recruited from the NASH CRN observational study, of which 45% had fibrosis stage 2–4.8 After considering a number of machine learning methods, the model was constructed using logistic regression. Data on age, body mass index, diabetes as a binary variable, AST, ALT, total globulin and platelets were included. The area under the ROC curve for this model to correctly define presence of significant fibrosis was 0.79 in the training data set, and 0.80 in an external validation data set, consisting of participants in the FLINT trial. Further validation was performed in a separate cohort of patients with MRE‐defined fibrosis. Finally, the authors investigated the prognostic performance of the SAFE score in the NHANES data set and found that higher levels of the score were associated with a higher overall mortality. Unfortunately, only overall mortality could be ascertained and not liver‐specific mortality or non‐fatal events. The authors compared the SAFE score to that of established diagnostic models (FIB‐4 and NAFLD fibrosis score9) where SAFE outperformed these in both the derivation and validation cohorts. Interestingly, many of the included parameters are strikingly similar to those included in the NAFLD fibrosis score. So, should we switch to recommending the SAFE score as a first‐line tool in primary care instead of FIB‐4 or other scores? Perhaps not so fast. The model was developed in a context where it is not intended to be used.10 Ideally, a diagnostic or prediction model should be developed in the cohorts where it would be applied, in this case in primary care. In secondary or tertiary care, other non‐invasive alternatives to biopsy such as vibration‐controlled transient elastography with higher diagnostic accuracy are often available as alternatives to blood‐based models. The problem can be visualized by the use of SAFE in the NHANES data set. In those with presumed NAFLD, only 58% were defined as at low risk using the suggested cut‐offs. 34% were defined as at indeterminate risk and 8% as high risk. By contrast, an analysis of the FIB‐4 score in a Swedish general population cohort found that 1.4% were classified as high risk.7 Thus, using the SAFE score in primary care could as of now lead to a high proportion of false‐positives and risk overwhelming hepatology services. Another drawback of the SAFE score is the use of more parameters compared with for instance FIB‐4, meaning that it could be more difficult to implement on a wider stage. The authors conclude that it is unknown how their score is best used in a primary care setting, to which one must fully agree. Recalibration of the SAFE score using a primary care cohort would be a natural next step, and such studies could be interesting to the community. Extensive validation of new clinical diagnostic or prediction models needs to be performed before use in clinical practice, and the community need to decide on which model is most proper to use in different settings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
你好吗发布了新的文献求助10
刚刚
cc完成签到,获得积分20
刚刚
刚刚
一蓑烟雨任完成签到,获得积分10
刚刚
1秒前
坚定水之完成签到 ,获得积分10
1秒前
Guan发布了新的文献求助10
1秒前
CodeCraft的应助被Mine采纳,获得10
1秒前
xbb完成签到,获得积分10
1秒前
眼睛大的香水完成签到 ,获得积分20
2秒前
huiliyii发布了新的文献求助10
2秒前
2秒前
Ht0118完成签到,获得积分10
3秒前
英姑的应助被高高书本采纳,获得10
3秒前
3秒前
再见不难完成签到,获得积分10
3秒前
青椒发布了新的文献求助10
3秒前
4秒前
哈基米完成签到,获得积分10
4秒前
4秒前
zaq66996发布了新的文献求助10
4秒前
领导范儿的应助被机智飞丹采纳,获得10
4秒前
852的应助被叶落风行采纳,获得30
4秒前
聪明眼睛完成签到,获得积分10
4秒前
cathy完成签到 ,获得积分10
4秒前
馒头就辣条完成签到 ,获得积分10
4秒前
shuyiWang发布了新的文献求助10
4秒前
清欢渡发布了新的文献求助10
4秒前
5秒前
科研通AI6.4的应助被新手采纳,获得10
5秒前
羊与布克发布了新的文献求助10
5秒前
李健的小迷弟的应助被Tuniverse_采纳,获得10
5秒前
drizzle完成签到,获得积分10
5秒前
小Di完成签到 ,获得积分10
6秒前
豆花鱼由于求助违规,被管理员扣积分10
6秒前
科研通AI6.4的应助被chenchen采纳,获得10
6秒前
6秒前
7秒前
7秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182602
求助须知:如何正确求助?哪些是违规求助? 9572033
关于积分的说明 21821767
捐赠科研通 7779061
什么是DOI,文献DOI怎么找? 3433684
关于科研通互助平台的介绍 2557863
邀请新用户注册赠送积分活动 2479732